Akebia Therapeutics (AKBA) Capital Expenditures Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) Capital Expenditures Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 75.58% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 28.56% |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn | -35.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.66% |
| Sep 30, 2025 | -80.34% |
| Jun 30, 2025 | 26.43% |
| Mar 31, 2025 | 26.09% |
| Sep 30, 2024 | -51.40% |
| Jun 30, 2024 | 27.44% |
| Mar 31, 2024 | 34.82% |
| Dec 31, 2023 | -29.79% |
| Sep 30, 2023 | 7.53% |
| Jun 30, 2023 | -534.66% |
| Mar 31, 2023 | 298.18% |
| Sep 30, 2022 | 58.79% |
| Jun 30, 2022 | -71.64% |
| Mar 31, 2022 | -59.49% |
| Sep 30, 2021 | 82.09% |
| Jun 30, 2021 | -134.21% |
| Mar 31, 2021 | -87.56% |
| Dec 31, 2020 | -79.55% |
| Sep 30, 2020 | 347.59% |
| Jun 30, 2020 | 68.38% |